<DOC>
	<DOCNO>NCT02593760</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study evaluate efficacy safety vismodegib plus ( + ) ruxolitinib versus placebo + ruxolitinib participant intermediate- high-risk MF . The study divide 2 component . The Phase 1b portion study start 6-week safety run-in period 10 participant receive vismodegib ( 150 milligram [ mg ] orally [ PO ] daily [ QD ] ) + ruxolitinib ( PO twice daily [ BID ] ) assessment acute safety event associate combined therapy . After get confirmation safety toxicity combination , Phase 3 randomization portion study begin approximately 84 participant randomly assign 1:1 ratio receive either vismodegib ( 150 mg PO QD ) plus ruxolitinib ( PO BID ) placebo ( PO QD ) plus ruxolitinib ( PO BID ) 48 week withdrawal discontinuation , whichever occur first .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Vismodegib ( Erivedge ) Combination With Ruxolitinib Treatment Intermediate- High-Risk Myelofibrosis ( MF )</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Pathologically confirm diagnosis primary MF , postpolycythemia vera MF , postessential thrombocythemia MF , accord 2008 revised World Health Organization criterion Intermediate1 , intermediate2 , highrisk accord International Working Group Myeloproliferative Neoplasms Research Treatment ( IWGMRT ) Dynamic International Prognostic Scoring System ( DIPSS ) Participants age great equal ( &gt; = ) 18 year Life expectancy &gt; =6 month Peripheral blood blast count le ( &lt; ) 10 % Palpable splenomegaly great ( &gt; ) 5 centimeter ( cm ) leave costal margin Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 Adequate hepatic renal function assess : Total bilirubin less equal ( &lt; = ) 2.0*upper limit normal ( ULN ) , unless result hemolysis Gilbert 's Syndrome Aspartate transaminase alanine transaminase &lt; =2.5*ULN ( &lt; =5*ULN liver involve extramedullary hematopoiesis determine investigator ) Serum creatinine &lt; =1.5*ULN creatinine clearance great ( &gt; ) 30 milliliter per minute ( mL/min ) Prior treatment Hedgehog Janus kinase ( JAK ) pathway inhibitor Treatment strong cytochrome P450 ( CYP ) 3A4 inhibitors/inducers within 28 day prior Day 1 Prior therapy treatment intermediate highrisk MF include chemotherapy , interferon , thalidomide , busulfan , lenalidomide , anagrelide , androgen within 28 day prior Day 1 Prior splenectomy splenic irradiation Inadequate bone marrow reserve follow : Absolute neutrophil count &lt; =1000/microliters ( mcL ) Platelet count &lt; 100,000/mcL without assistance growth factor , thrombopoietic factor , platelet transfusion Participants history platelet count &lt; 50,000/mccL ANC &lt; 500/mL , except treatment myeloproliferative neoplasm ( MPN ) treatment cytotoxic therapy reason Planned allogeneic bone marrow transplant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>